160 related articles for article (PubMed ID: 35477310)
1. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin.
Ranallo N; Bocchini M; Menis J; Pilotto S; Severi S; Liverani C; Bongiovanni A
Expert Rev Anticancer Ther; 2022 Jun; 22(6):597-603. PubMed ID: 35477310
[TBL] [Abstract][Full Text] [Related]
2. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
4. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
6. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
7. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.
Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC
Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK
Future Oncol; 2022 Aug; 18(24):2639-2649. PubMed ID: 35815644
[TBL] [Abstract][Full Text] [Related]
10. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
Zhang H; Yang Y; Li X; Yuan X; Chu Q
Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960
[TBL] [Abstract][Full Text] [Related]
12. Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy.
Matsuo K; Taniguchi K; Hamamoto H; Ito Y; Futaki S; Inomata Y; Shima T; Asakuma M; Lee SW; Tanaka K; Okuda J; Kondo Y; Uchiyama K
Cancer Sci; 2019 Oct; 110(10):3122-3131. PubMed ID: 31369178
[TBL] [Abstract][Full Text] [Related]
13. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
[TBL] [Abstract][Full Text] [Related]
15. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
[TBL] [Abstract][Full Text] [Related]
16. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
[TBL] [Abstract][Full Text] [Related]
18. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
[TBL] [Abstract][Full Text] [Related]
19. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice.
Deng SM; Yan XC; Liang L; Wang L; Liu Y; Duan JL; Yang ZY; Chang TF; Ruan B; Zheng QJ; Han H
Biochem Biophys Res Commun; 2017 Jan; 483(1):488-494. PubMed ID: 28007595
[TBL] [Abstract][Full Text] [Related]
20. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
